CNBC·3 min read·medium
Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market
A
Annika Kim Constantino
✦AI Summary
Eli Lilly and Novo Nordisk both reported strong second-quarter earnings, but investors are favoring Lilly due to its dominant market share and clearer growth trajectory. While both companies raised their outlooks, Lilly's obesity and diabetes drugs are currently outperforming Novo's offerings in the U.S. market.
The diverging paths of two GLP-1 drugmakers were on full display this week.
businesshealtheconomy
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in